Systematic Review: Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved and Mildly Reduced Ejection Fraction
Authors:
- Marcus Vinicius SimõesMSMarcus Vinicius Simões
- Marcus ViniciusMVMarcus Vinicius
- Luiz Claudio DanzmannLDLuiz Claudio Danzmann
- Sílvia Marinho MartinsSMSílvia Marinho Martins
- José Albuquerque de Figueiredo NetoJNJosé Albuquerque de Figueiredo Neto
- Fabiana G. Marcondes-BragaFMFabiana G. Marcondes-Braga
- Ricardo Mourilhe-RochaRMRicardo Mourilhe-Rocha
- Denilson Campos de AlbuquerqueDADenilson Campos de Albuquerque
- Mucio Tavares de Oliveira JrMJMucio Tavares de Oliveira Jr
Open Access
- 1 January 2026
- journal article
- review article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Abstract
Heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) is a prevalent condition associated with significant morbidity and mortality, and the benefits of mineralocorticoid receptor antagonists (MRAs) remain unclear. To develop a systematic review on the use of MRAs in patients with HFpEF or HFmrEF, a systematic review and meta-analysis were conducted using a broad search strategy in the following databases: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL). Randomized controlled trials that evaluated the use of MRAs in patients with HFpEF compared to control groups were included. The quality of evidence and the strength of the recommendation were assessed according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. Eight studies were included. No statistically significant differences were observed for the outcomes of overall mortality and cardiovascular mortality compared to the control group for any of the MRAs. A benefit was observed with a reduced risk of hospitalization for heart failure (relative risk: 0.87; 95% confidence interval: 0.79 to 0.96; moderate certainty of evidence) and of worsening heart failure events (relative risk: 0.83; 95% confidence interval: 0.77 to 0.89; high certainty of evidence). The results of the meta-analysis indicate a significant benefit from MRAs, spironolactone or finerenone, to reduce hospitalizations and worsening heart failure events in patients with HFpEF or HFmrEF. Mineralocorticoid Receptor Antagonists; Diastolic Heart Failure; Systolic Heart Failure; Systematic Review; Meta-Analysis.Keywords
This publication has 23 references indexed in Scilit:
- Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection FractionJAMA Cardiology, 2025
- Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2024
- Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviewsJournal of Clinical Epidemiology, 2021
- Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trialsHeart and Vessels, 2018
- Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection FractionJACC, 2016
- Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection FractionJournal of Cardiac Failure, 2014
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection FractionJAMA, 2013
- Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)Journal of Cardiac Failure, 2011
- Natural History of Markers of Collagen Turnover in Patients With Early Diastolic Dysfunction and Impact of EplerenoneJACC, 2009
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999